Ferric Carboxymaltose in Patients with Heart Failure and Iron Deficiency
Open accessThe DOI matches its Crossref record; 25 of the 26 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Iron deficiency may impair aerobic performance. This study aimed to determine whether treatment with intravenous iron (ferric carboxymaltose) would improve symptoms in patients who had heart failure, reduced left ventricular ejection fraction, and iron deficiency, either with or without anemia. METHODS: We enrolled 459 patients with chronic heart failure of New York Heart Association (NYHA) functional class II or III, a left ventricular ejection fraction of 40% or less (for patients with NYHA class II) or 45% or less (for NYHA class III), iron deficiency (ferritin level <100 microg per liter or between 100 and 299 microg per liter, if the transferrin saturation was <20%), and a hemoglobin level of 95 to 135 g per liter. Patients were randomly assigned, in a 2:1 ratio, to receive 200 mg of intravenous iron (ferric carboxymaltose) or saline (placebo). The primary end points were the self-reported Patient Global Assessment and NYHA functional class, both at week 24. Secondary end points included the distance walked in 6 minutes and the health-related quality of life. RESULTS: Among the patients receiving ferric carboxymaltose, 50% reported being much or moderately improved, as compared with 28% of patients receiving placebo, according to the Patient Global Assessment (odds ratio for improvement, 2.51; 95% confidence interval [CI], 1.75 to 3.61). Among the patients assigned to ferric carboxymaltose, 47% had an NYHA functional class I or II at week 24, as compared with 30% of patients assigned to placebo (odds ratio for improvement by one class, 2.40; 95% CI, 1.55 to 3.71). Results were similar in patients with anemia and those without anemia. Significant improvements were seen with ferric carboxymaltose in the distance on the 6-minute walk test and quality-of-life assessments. The rates of death, adverse events, and serious adverse events were similar in the two study groups. CONCLUSIONS: Treatment with intravenous ferric carboxymaltose in patients with chronic heart failure and iron deficiency, with or without anemia, improves symptoms, functional capacity, and quality of life; the side-effect profile is acceptable. (ClinicalTrials.gov number, NCT00520780).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Likewise, parenteral iron substitution has been found to improve the clinical course of CHF in patients with coexisting ID [22–24].”
From Iron deficiency or anemia of inflammation?: Differential diagnosis and mechanisms of anemia of inflammation (2016) · cites this paper as [24]
In the citing paper
“We are aware that anemia is a complication of iron deficiency, though not the only one, since other tissues/organs may be iron-depleted before anemia develops, as occurs in chronic heart failure.75”
From Iron metabolism and iron disorders revisited in the hepcidin era (2020) · cites this paper as [75]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing
Benjamini, Y., & Hochberg, Y. (1995) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1995.tb02031.x · Cited by 109,482
EQ-SD: a measure of health status from the EuroQol Group
Rabin, R., & Charro, F. D. (2001) · Annals of Medicine · doi:10.3109/07853890109002087 · Cited by 5,613
Regression Models for Ordinal Data
McCullagh, P. (1980) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1980.tb01109.x · Cited by 4,453
2005 WRITING COMMITTEE MEMBERS, Hunt, S. A., Abraham, W. T., Chin, M. H., Feldman, A. M., Francis, G. S., Ganiats, T. G., Jessup, M., Konstam, M. A., Mancini, D. M., et al. (2009) · Circulation · doi:10.1161/circulationaha.109.192065 · Cited by 3,720
ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008
Dickstein, K., Authors/Task Force Members, Cohen-Solal, A., Filippatos, G., McMurray, J. J. V., Ponikowski, P., Poole-Wilson, P. A., Strömberg, A., van Veldhuisen, D. J., Atar, D., et al. (2008) · European Journal of Heart Failure · doi:10.1016/j.ejheart.2008.08.005 · Cited by 3,512
Self-citationGreen, C. P., Porter, C. B., Bresnahan, D. R., & Spertus, J. A. (2000) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(00)00531-3 · Cited by 1,827
Trends in Heart Failure Incidence and Survival in a Community-Based Population
Roger, V. L. (2004) · JAMA · doi:10.1001/jama.292.3.344 · Cited by 1,600
Jessup, M., & Brozena, S. (2003) · New England Journal of Medicine · doi:10.1056/nejmra021498 · Cited by 1,564
Hunt, S. A., Abraham, W. T., Chin, M. H., Feldman, A. M., Francis, G. S., Ganiats, T. G., Jessup, M., Konstam, M. A., Mancini, D. M., Michl, K., et al. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.11.013 · Cited by 1,374
Haas, J. D., & Brownlie, T. (2001) · The Journal of Nutrition · doi:10.1093/jn/131.2.676s · Cited by 1,186
Research works printed but not linked: 4
- Fairbanks V, Beutler E. Iron deficiency. In: Beutler E, ed. Williams hematology. 6th ed. New York: McGraw-Hill, 2001:295-304, 447-70.
- Davies KJ, 1982, Am J Physiol, 242, E418
- Usmanov RI, 2008, J Nephrol, 21, 236
- Ganzoni AM, 1970, Schweiz Med Wochenschr, 100, 301
Cited by
Items 101–200 of 1,002
Comín-Colet, J., Enjuanes, C., González, G., Torrens, A., Cladellas, M., Meroño, O., Ribas, N., Ruiz, S., Gómez, M., Verdú, J. M., et al. (2013) · European Journal of Heart Failure · doi:10.1093/eurjhf/hft083 · Cited by 213
Anemia and iron deficiency in heart failure: mechanisms and therapeutic approaches
van Veldhuisen, D. J., Anker, S. D., Ponikowski, P., & Macdougall, I. C. (2011) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2011.77 · Cited by 210
“Nevertheless, the criteria most-commonly used for detecting this condition are a ferritin level”
BackgroundSelf-citation2024 Clinical practice guidelines for Chronic heart failure
Galyavich, A. S., Tereshchenko, S. N., Uskach, T. M., Ageev, F. T., Aronov, D. M., Arutyunov, G. P., Begrambekova, Y. L., Belenkov, Y. N., Boytsov, S. A., Bubnova, M. G., et al. (2024) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2024-6162 · Cited by 204
Iron deficiency is common in idiopathic pulmonary arterial hypertension
Ruiter, G., Lankhorst, S., Boonstra, A., Postmus, P. E., Zweegman, S., Westerhof, N., van der Laarse, W. J., & Vonk-Noordegraaf, A. (2011) · European Respiratory Journal · doi:10.1183/09031936.00100510 · Cited by 211
Iron deficiency and cardiovascular disease
Savarese, G., von Haehling, S., Butler, J., Cleland, J. G. F., Ponikowski, P., & Anker, S. D. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehac569 · Cited by 200
“At Week 24, compared with placebo, FCM improved patient global assessment, NYHA class, 6MWD, and HRQoL, without any difference in mortality and adverse/serious events, regardless of anaemia.(39,49,50) Notably in patients without anaemia, these benefits were seen despite no change in haemoglobin.”
MethodSelf-citationIron deficiency: new insights into diagnosis and treatment
Camaschella, C. (2015) · Hematology · doi:10.1182/asheducation-2015.1.8 · Cited by 201
JCS/JHFS 2025 Guideline on Diagnosis and Treatment of Heart Failure
Kitai, T., Kohsaka, S., Kato, T., Kato, E., Sato, K., Teramoto, K., Yaku, H., Akiyama, E., Ando, M., Izumi, C., et al. (2025) · Circulation Journal · doi:10.1253/circj.cj-25-0002 · Cited by 191
A randomized trial of intravenous and oral iron in chronic kidney disease
Agarwal, R., Kusek, J. W., & Pappas, M. K. (2015) · Kidney International · doi:10.1038/ki.2015.163 · Cited by 200
Aapro, M., Österborg, A., Gascón, P., Ludwig, H., & Beguin, Y. (2012) · Annals of Oncology · doi:10.1093/annonc/mds112 · Cited by 196
Enjuanes, C., Klip, I. T., Bruguera, J., Cladellas, M., Ponikowski, P., Banasiak, W., van Veldhuisen, D. J., van der Meer, P., Jankowska, E. A., & Comín-Colet, J. (2014) · International Journal of Cardiology · doi:10.1016/j.ijcard.2014.03.169 · Cited by 197
Self-citationCriteria for Iron Deficiency in Patients With Heart Failure
Masini, G., Graham, F. J., Pellicori, P., Cleland, J. G. F., Cuthbert, J. J., Kazmi, S., Inciardi, R. M., & Clark, A. L. (2022) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.11.039 · Cited by 193
“001 Edema ($ankle) 355 (8) 322 (25) 227 (30) 576 (34) 93 (34) <0.”
Klein, A. A., Collier, T. J., Brar, M. S., Evans, C., Hallward, G., Fletcher, S. N., Richards, T., & the Association of Cardiothoracic Anaesthetists (ACTA) (2016) · Anaesthesia · doi:10.1111/anae.13423 · Cited by 192
An essential cell-autonomous role for hepcidin in cardiac iron homeostasis
Lakhal-Littleton, S., Wolna, M., Chung, Y. J., Christian, H. C., Heather, L. C., Brescia, M., Ball, V., Diaz, R., Santos, A., Biggs, D., et al. (2016) · eLife · doi:10.7554/elife.19804 · Cited by 184
“Furthermore, several clinical trials have now established the benefits of intravenous iron supplementation in CHF patients, with or without anaemia (Ponikowski et al., 2015; Anker et al., 2009; Avni et al., 2012).”
BackgroundModern iron replacement therapy: clinical and pathophysiological insights
Girelli, D., Ugolini, S., Busti, F., Marchi, G., & Castagna, A. (2018) · International Journal of Hematology · doi:10.1007/s12185-017-2373-3 · Cited by 188
Bailie, G. R., Larkina, M., Goodkin, D. A., Li, Y., Pisoni, R. L., Bieber, B., Mason, N., Tong, L., Locatelli, F., Marshall, M. R., et al. (2015) · Kidney International · doi:10.1038/ki.2014.275 · Cited by 186
Martens, P., Nijst, P., Verbrugge, F. H., Smeets, K., Dupont, M., & Mullens, W. (2018) · Acta Cardiologica · doi:10.1080/00015385.2017.1351239 · Cited by 181
“This is in clear contrast to the evidence emanating from the three well-conducted randomised controlled trials (FAIR-HF, CONFIRM-HF and EFFECT-HF), illustrating no difference in benefit of ferric carboxymaltose in iron deficient patients with or without presence of anaemia [10,11,16].”
ResultRole of iron metabolism in heart failure: From iron deficiency to iron overload
Zhang, H., Zhabyeyev, P., Wang, S., & Oudit, G. Y. (2019) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2018.08.030 · Cited by 181
Iron-regulatory proteins secure iron availability in cardiomyocytes to prevent heart failure
Haddad, S., Wang, Y., Galy, B., Korf-Klingebiel, M., Hirsch, V., Baru, A. M., Rostami, F., Reboll, M. R., Heineke, J., Flögel, U., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw333 · Cited by 181
Myocardial and Systemic Iron Depletion in Heart Failure
Maeder, M. T., Khammy, O., dos Remedios, C., & Kaye, D. M. (2011) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2011.01.059 · Cited by 178
Comin-Colet, J., Lainscak, M., Dickstein, K., Filippatos, G. S., Johnson, P., Lüscher, T. F., Mori, C., Willenheimer, R., Ponikowski, P., & Anker, S. D. (2013) · European Heart Journal · doi:10.1093/eurheartj/ehr504 · Cited by 175
Self-citationPrevalence and Outcomes of Anemia and Hematinic Deficiencies in Patients With Chronic Heart Failure
Cleland, J. G. F., Zhang, J., Pellicori, P., Dicken, B., Dierckx, R., Shoaib, A., Wong, K., Rigby, A., Goode, K., & Clark, A. L. (2016) · JAMA Cardiology · doi:10.1001/jamacardio.2016.1161 · Cited by 175
The role of iron repletion in adult iron deficiency anemia and other diseases
Elstrott, B., Khan, L., Olson, S., Raghunathan, V., DeLoughery, T., & Shatzel, J. J. (2020) · European Journal of Haematology · doi:10.1111/ejh.13345 · Cited by 166
Mansour, D., Hofmann, A., & Gemzell-Danielsson, K. (2021) · Advances in Therapy · doi:10.1007/s12325-020-01564-y · Cited by 167
Kotzé, A., Harris, A., Baker, C., Iqbal, T., Lavies, N., Richards, T., Ryan, K., Taylor, C., & Thomas, D. (2015) · British Journal of Haematology · doi:10.1111/bjh.13623 · Cited by 161
The available intravenous iron formulations: History, efficacy, and toxicology
Auerbach, M., & Macdougall, I. (2017) · Hemodialysis International · doi:10.1111/hdi.12560 · Cited by 157
The Burden of Iron Deficiency in Heart Failure
Rocha, B. M. L., Cunha, G., & Falcão, L. F. D. M. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.12.027 · Cited by 187
Iron Deficiency in Heart Failure: Mechanisms and Pathophysiology
Alnuwaysir, R. I. S., Hoes, M. F., van Veldhuisen, D. J., van der Meer, P., & Beverborg, N. G. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm11010125 · Cited by 198
“The ESC definition of ID (also called the FAIR-HF definition [22]) is limited by relying heavily on ferritin levels, thereby labelling patients with TSAT ≤20%, but a ferritin >300 μg/mL as iron sufficient, while labelling those with isolated hypoferritinaemia (ferritin <100 μg/mL with a TSAT >20%) as iron deficient.”
BackgroundIron Metabolism in Cardiovascular Disease: Physiology, Mechanisms, and Therapeutic Targets
Sawicki, K. T., Jesus, A. D., & Ardehali, H. (2023) · Circulation Research · doi:10.1161/circresaha.122.321667 · Cited by 179
Iron metabolism and iron supplementation in cancer patients
Ludwig, H., Evstatiev, R., Kornek, G. V., Aapro, M., Bauernhofer, T., Buxhofer‐Ausch, V., Fridrik, M., Geissler, D., Geissler, K. H., Gisslinger, H., et al. (2015) · Wiener klinische Wochenschrift · doi:10.1007/s00508-015-0842-3 · Cited by 170
Filippatos, G., Farmakis, D., Colet, J. C., Dickstein, K., Lüscher, T. F., Willenheimer, R., Parissis, J., Gaudesius, G., Mori, C., von Eisenhart Rothe, B., et al. (2013) · European Journal of Heart Failure · doi:10.1093/eurjhf/hft099 · Cited by 157
Self-citationLanser, L., Fuchs, D., Kurz, K., & Weiß, G. (2021) · Nutrients · doi:10.3390/nu13113732 · Cited by 211
High Prevalence of Iron Deficiency in Patients with Acute Decompensated Heart Failure
Cohen-Solal, A., Damy, T., Terbah, M., Kerebel, S., Baguet, J.-P., Hanon, O., Zannad, F., Laperche, T., Leclercq, C., Concas, V., et al. (2014) · European Journal of Heart Failure · doi:10.1002/ejhf.139 · Cited by 153
Self-citationOnken, J. E., Bregman, D. B., Harrington, R. A., Morris, D., Acs, P., Akright, B., Barish, C., Bhaskar, B. S., Smith‐Nguyen, G. N., Butcher, A., et al. (2014) · Transfusion · doi:10.1111/trf.12289 · Cited by 154
Charles‐Edwards, G., Amaral, N., Sleigh, A., Ayis, S. A., Catibog, N., McDonagh, T. A., Monaghan, M. J., Amin-Youssef, G. F., Kemp, G. J., Shah, A. M., et al. (2019) · Circulation · doi:10.1161/circulationaha.118.038516 · Cited by 168
Block, G. A., Fishbane, S. N., Rodríguez, M., Smits, G., Shemesh, S., Pérgola, P. E., Wolf, M. S., & Chertow, G. M. (2014) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2014.10.014 · Cited by 154
Iron Deficiency in Heart Failure and Effect of Dapagliflozin: Findings From DAPA-HF
Docherty, K. F., Welsh, P. I., Verma, S., de Boer, R. A., O’Meara, E., Bengtsson, O., Køber, L., Kosiborod, M., Hammarstedt, A., Langkilde, A. M., et al. (2022) · Circulation · doi:10.1161/circulationaha.122.060511 · Cited by 177
Self-citationNairz, M., Theurl, I., Wolf, D., & Weiss, G. (2016) · Wiener Medizinische Wochenschrift · doi:10.1007/s10354-016-0505-7 · Cited by 152
Stugiewicz, M., Tkaczyszyn, M., Kasztura, M., Banasiak, W., Ponikowski, P., & Jankowska, E. A. (2016) · European Journal of Heart Failure · doi:10.1002/ejhf.467 · Cited by 150
Self-citationIron Therapy for the Treatment of Iron Deficiency in Chronic Heart Failure: Intravenous or Oral?
McDonagh, T., & Macdougall, I. C. (2015) · European Journal of Heart Failure · doi:10.1002/ejhf.236 · Cited by 149
Krum, H., Jelinek, M. V., Stewart, S., Sindone, A., & Atherton, J. J. (2011) · Medical Journal of Australia · doi:10.5694/j.1326-5377.2011.tb03031.x · Cited by 147
Anaemia in inflammatory rheumatic diseases
Weiss, G., & Schett, G. (2013) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2012.183 · Cited by 146
Lactoferrin in aseptic and septic inflammation
Lepanto, M. S., Rosa, L., Paesano, R., Valenti, P., & Cutone, A. (2019) · Molecules · doi:10.3390/molecules24071323 · Cited by 147
“AI is common in patients suffering from chronic diseases with prolonged inflammation due to aseptic diseases as cancer and obesity [75,76].”
BackgroundMyocardial energetics in heart failure
Nickel, A. G., Löffler, J., & Maack, C. (2013) · Basic Research in Cardiology · doi:10.1007/s00395-013-0358-9 · Cited by 156
Cardiorenal syndrome—current understanding and future perspectives
Braam, B. G., Joles, J. A., Danishwar, A. H., & Gaillard, S. (2013) · Nature Reviews Nephrology · doi:10.1038/nrneph.2013.250 · Cited by 155
Ito, J., Omiya, S., Rusu, M.-C., Ueda, H., Murakawa, T., Tanada, Y., Abe, H., Nakahara, K., Asahi, M., Taneike, M., et al. (2021) · eLife · doi:10.7554/elife.62174 · Cited by 150
Shah, A., Donovan, K., Seeley, C., Dickson, E. A., Palmer, A. J. R., Doree, C. J., Brunskill, S. J., Reid, J., Acheson, A. G., Sugavanam, A., et al. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.33935 · Cited by 167
Clevenger, B., & Richards, T. (2014) · Anaesthesia · doi:10.1111/anae.12918 · Cited by 173
Yeo, T. J., Yeo, P. S. D., Ching-Chiew Wong, R., Ong, H. Y., Leong, K. T. G., Jaufeerally, F., Sim, D., Santhanakrishnan, R., Lim, S. L., Chan, M. M. Y., et al. (2014) · European Journal of Heart Failure · doi:10.1002/ejhf.161 · Cited by 141
Iron supplementation to treat anemia in patients with chronic kidney disease
Besarab, A., & Coyne, D. W. (2010) · Nature Reviews Nephrology · doi:10.1038/nrneph.2010.139 · Cited by 158
Moore, R. A., Gaskell, H., Rose, P. E., & Allan, J. (2011) · BMC Blood Disorders · doi:10.1186/1471-2326-11-4 · Cited by 142
Reduction in mitochondrial iron alleviates cardiac damage during injury
Chang, H., Wu, R., Shang, M., Sato, T., Chen, C., Shapiro, J. S., Liu, T., Thakur, A., Sawicki, K. T., Prasad, S. V., et al. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201505748 · Cited by 138
Management of Iron Deficiency Anemia.
(2015) · PubMed Central · Cited by 136
von Haehling, S., Gremmler, U., Krumm, M., Mibach, F., Schön, N., Taggeselle, J., Dahm, J. B., & Angermann, C. E. (2017) · Clinical Research in Cardiology · doi:10.1007/s00392-016-1073-y · Cited by 155
Novel therapeutic targets for the treatment of heart failure
Tamargo, J. L., & Lopez-Sendon, J. L. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3431 · Cited by 142
Intravenous Iron in Patients with Heart Failure and Iron Deficiency: An Updated Meta-Analysis
Graham, F. J., Pellicori, P., Kalra, P. R., Ford, I., Bruzzese, D., & Cleland, J. G. F. (2023) · European Journal of Heart Failure · doi:10.1002/ejhf.2810 · Cited by 159
Ebner, N., Jankowska, E. A., Ponikowski, P., Lainscak, M., Elsner, S., Sliziuk, V., Steinbeck, L., Kube, J., Bekfani, T., Scherbakov, N., et al. (2016) · International Journal of Cardiology · doi:10.1016/j.ijcard.2015.11.178 · Cited by 131
“Moreover, it was previously shown that the presence of an iron deficit is an independent therapeutic target [12].”
BackgroundMethodInfluentialSelf-citationRössler, J., Schoenrath, F., Seifert, B., Kaserer, A., Spahn, G. H., Falk, V., & Spahn, D. R. (2020) · British Journal of Anaesthesia · doi:10.1016/j.bja.2019.09.016 · Cited by 132
Ponikowski, P. P., Mentz, R. J., Hernandez, A. F., Butler, J., Khan, M. S., van Veldhuisen, D. J., Roubert, B., Blackman, N. J., Friede, T., Jankowska, E. A., et al. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad586 · Cited by 153
Self-citationFavrat, B., Balck, K., Breymann, C., Hedenus, M., Keller, T., Mezzacasa, A., & Gasche, C. (2014) · PLoS ONE · doi:10.1371/journal.pone.0094217 · Cited by 130
“Since controlled studies of FCM in different patient populations confirmed a positive benefit/risk ratio for treatment with a single FCM dose of 1000 mg iron [34],[37],[45], and a prior pilot study in a similar population suggested a beneficial effect of iron sucrose given at a total dose of 800 mg iron, the approved…”
Guía ESC 2021 sobre el diagnóstico y tratamiento de la insuficiencia cardiaca aguda y crónica
McDonagh, T. A., Metra, M., Adamo, M., Gardner, R. S., Baumbach, A., Böhm, M., Burri, H., Butler, J., Čelutkienė, J., Chioncel, O. D., et al. (2022) · Revista Española de Cardiología · doi:10.1016/j.recesp.2021.11.027 · Cited by 178
Ferric Carboxymaltose: A Review of Its Use in Iron Deficiency
Keating, G. M. (2014) · Drugs · doi:10.1007/s40265-014-0332-3 · Cited by 138
Onken, J. E., Bregman, D. B., Harrington, R. A., Morris, D., Buerkert, J. E., Hamerski, D., Iftikhar, H., Mangoo‐Karim, R., Martin, E. R., Martínez, C. O. A., et al. (2013) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gft251 · Cited by 133
Girelli, D., Marchi, G., & Camaschella, C. (2018) · HemaSphere · doi:10.1097/hs9.0000000000000040 · Cited by 161
UK guidelines for referral and assessment of adults for heart transplantation
Banner, N. R., Bonser, R. S., Clark, A. L., Clark, S., Cowburn, P. J., Gardner, R. S., Kalra, P. R., McDonagh, T., Rogers, C. A., Swan, L., et al. (2011) · Heart · doi:10.1136/heartjnl-2011-300048 · Cited by 126
Avni, T., Leibovici, L., & Gafter-Gvili, A. (2012) · European Journal of Heart Failure · doi:10.1093/eurjhf/hfs017 · Cited by 125
Anaemia, Iron Deficiency and Heart Failure in 2020: Facts and Numbers
Chopra, V., & Anker, S. D. (2020) · ESC Heart Failure · doi:10.1002/ehf2.12797 · Cited by 124
Self-citationCotroneo, E., Ashek, A., Wang, L., Wharton, J., Dubois, O., Bozorgi, S., Busbridge, M., Alavian, K. N., Wilkins, M. R., & Zhao, L. (2015) · Circulation Research · doi:10.1161/circresaha.116.305265 · Cited by 142
Iron Deficiency Anemia—Bridging the Knowledge and Practice Gap
Shander, A., Goodnough, L. T., Javidroozi, M., Auerbach, M., Carson, J. L., Ershler, W. B., Ghiglione, M., Glaspy, J. A., & Lew, I. (2014) · Transfusion Medicine Reviews · doi:10.1016/j.tmrv.2014.05.001 · Cited by 130
Iron deficiency beyond erythropoiesis: should we be concerned?
Musallam, K. M., & Taher, A. T. (2018) · Current Medical Research and Opinion · doi:10.1080/03007995.2017.1394833 · Cited by 122
McDonagh, T., Damy, T., Doehner, W., Lam, C. S. P., Sindone, A., van der Meer, P., Cohen-Solal, A., Kindermann, I., Manito, N., Pfister, O., et al. (2018) · European Journal of Heart Failure · doi:10.1002/ejhf.1305 · Cited by 121
Colet, J. C., Verdú-Rotellar, J. M., Vela, E., Clèries, M., Bustins, M., Mendoza, L., Badosa, N., Cladellas, M., Ferré, S., & Bruguera, J. (2014) · Revista Española de Cardiología · doi:10.1016/j.recesp.2013.12.007 · Cited by 134
Iron deficiency without anemia – a clinical challenge
Soppi, E. T. (2018) · Clinical Case Reports · doi:10.1002/ccr3.1529 · Cited by 121
“Notably patients with inflammation or clinically significantly impaired liver or renal function were excluded from the trial [10].”
BackgroundIron deficiency: an emerging therapeutic target in heart failure
Solal, A. C., Leclercq, C., Deray, G., Lasocki, S., Zambrowski, J.-J., Mebazaa, A., de Groote, P., Damy, T., & Galinier, M. (2014) · Heart · doi:10.1136/heartjnl-2014-305669 · Cited by 137
Díez‐Villanueva, P., Jiménez-Méndez, C., & Alfonso, F. (2016) · 老年心脏病学杂志:英文版 · doi:10.11909/j.issn.1671-5411.2016.02.009 · Cited by 174
Dysregulated iron metabolism in polycythemia vera: etiology and consequences
Ginzburg, Y. Z., Feola, M., Zimran, E., Várkonyi, J., Ganz, T., & Hoffman, R. (2018) · Leukemia · doi:10.1038/s41375-018-0207-9 · Cited by 149
Butler, J., Khan, M. S., Mori, C., Filippatos, G. S., Ponikowski, P., Comin-Colet, J., Roubert, B., Spertus, J. A., & Anker, S. D. (2020) · European Journal of Heart Failure · doi:10.1002/ejhf.1810 · Cited by 115
Self-citationvon Haehling, S., Arzt, M. E., Doehner, W., Edelmann, F., Evertz, R., Ebner, N., Herrmann‐Lingen, C., Garfias‐Veitl, T., Koziolek, M. J., Noutsias, M., et al. (2020) · European Journal of Heart Failure · doi:10.1002/ejhf.1838 · Cited by 126
Steinmetz, T., Tschechne, B., Harlin, O., Klement, B., Franzem, M., Wamhoff, J., Tesch, H., Rohrberg, R., & Marschner, N. W. (2012) · Annals of Oncology · doi:10.1093/annonc/mds338 · Cited by 113
Beale, A. L., Warren, J. L., Roberts, N., Meyer, P., Townsend, N. P., & Kaye, D. (2019) · Open Heart · doi:10.1136/openhrt-2019-001012 · Cited by 112
The current and future management of acute heart failure syndromes
Pang, P. S., Komajda, M., & Gheorghiade, M. (2010) · European Heart Journal · doi:10.1093/eurheartj/ehq040 · Cited by 124
Iron deficiency as energetic insult to skeletal muscle in chronic diseases
Dzięgała, M., Josiak, K., Kasztura, M., Kobak, K. A., von Haehling, S., Banasiak, W., Anker, S. D., Ponikowski, P. P., & Jankowska, E. A. (2018) · Journal of Cachexia Sarcopenia and Muscle · doi:10.1002/jcsm.12314 · Cited by 123
Self-citationThe Impact of Intravenous Ferric Carboxymaltose on Renal Function: An Analysis of the FAIR-HF Study
Ponikowski, P. P., Filippatos, G. S., Colet, J. C., Willenheimer, R. B., Dickstein, K., Lüscher, T. F., Gaudesius, G., Rothe, B. V. E., Mori, C., Greenlaw, N., et al. (2015) · European Journal of Heart Failure · doi:10.1002/ejhf.229 · Cited by 122
Self-citationCladellas, M., Farré, N., Colet, J. C., Gómez, M., Meroño, O., Bosch, M., Vila, J., Molera, R., Segovia, A., & Bruguera, J. (2012) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2012.05.036 · Cited by 111
Emerging roles of ferroptosis in cardiovascular diseases
Wang, K., Chen, X., Wang, Y.-H., Cheng, X., Zhao, Y., Zhou, L., & Wang, K. (2022) · Cell Death Discovery · doi:10.1038/s41420-022-01183-2 · Cited by 123
“Treatment with iron supplements can improve symptoms to some extent, but the exact mechanism is not clear, and it may have potential risks [88].”
BackgroundMoe, G. W. P. L., Ezekowitz, J. A., O’Meara, E., Lepage, S., Howlett, J. G., Fremes, S. E., Al‐Hesayen, A., Heckman, G. A., Abrams, H. B., Ducharme, A., et al. (2014) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2014.10.022 · Cited by 120
Management of Heart Failure Patient with CKD
Banerjee, D., Rosano, G., & Herzog, C. A. (2021) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.14180920 · Cited by 139
Jankowska, E. A., Kirwan, B., Kosiborod, M., Butler, J., Anker, S. D., McDonagh, T. A., Dorobanţu, M., Dróżdż, J., Filippatos, G. S., Keren, A., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab234 · Cited by 122
Self-citationIron deficiency in pulmonary arterial hypertension: a potential therapeutic target
Rhodes, C. J., Wharton, J., Howard, L., Gibbs, J. S. R., Noordegraaf, A. V., & Wilkins, M. R. (2011) · European Respiratory Journal · doi:10.1183/09031936.00037711 · Cited by 117
Safety of intravenous iron formulations: facts and folklore.
Auerbach, M., & Macdougall, I. C. (2014) · PubMed · doi:10.2450/2014.0094-14 · Cited by 107
Ferric Carboxymaltose Prevents Recurrence of Anemia in Patients With Inflammatory Bowel Disease
Evstatiev, R., Alexeeva, O., Bokemeyer, B., Chopey, I. V., Felder, M., Gudehus, M., Iqbal, T. H., Халиф, И. Л., Marteau, P. R., Stein, J. M., et al. (2012) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2012.10.013 · Cited by 113
Ruiter, G., Manders, E., Happé, C. M., Schalij, I., Groepenhoff, H., Howard, L., Wilkins, M. R., Bogaard, H. J., Westerhof, N., van der Laarse, W. J., et al. (2015) · Pulmonary Circulation · doi:10.1086/682217 · Cited by 120
Sinnenberg, L. E., & Givertz, M. M. (2019) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2019.03.007 · Cited by 136
The relevance of congestion in the cardio-renal syndrome
Gnanaraj, J., von Haehling, S., Anker, S. D., Raj, D. S., & Radhakrishnan, J. (2012) · Kidney International · doi:10.1038/ki.2012.406 · Cited by 116
Self-citationAzab, B. N., Torbey, E., Hatoum, H. A., Singh, J., Khoueiry, G., Bachir, R. H., McGinn, J. T., McCord, D., & Lafferty, J. (2011) · Cardiology · doi:10.1159/000329920 · Cited by 107
Ferreira, J. P., Duarte, K., Graves, T., Zile, M. R., Abraham, W. T., Weaver, F. A., Lindenfeld, J. M., & Zannad, F. M. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.09.936 · Cited by 109
Beverborg, N. G., van Veldhuisen, D. J., & van der Meer, P. (2017) · JACC Heart Failure · doi:10.1016/j.jchf.2017.08.023 · Cited by 138
Bailie, G. R., Larkina, M., Goodkin, D. A., Li, Y., Pisoni, R. L., Bieber, B., Mason, N., Tong, L., Locatelli, F., Marshall, M. R., et al. (2013) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gft062 · Cited by 104
Bekfani, T., Pellicori, P., Morris, D. A., Ebner, N., Valentová, M., Sandek, A., Doehner, W., Cleland, J. G. F., Lainščak, M., Schulze, P. C., et al. (2018) · Clinical Research in Cardiology · doi:10.1007/s00392-018-1344-x · Cited by 108
Self-citationUnexplained iron deficiency in idiopathic and heritable pulmonary arterial hypertension
Soon, E., Treacy, C., Toshner, M. R., MacKenzie-Ross, R., Manglam, V., Busbridge, M., Sinclair-McGarvie, M., Arnold, J., Sheares, K. K. K., Morrell, N. W., et al. (2011) · Thorax · doi:10.1136/thx.2010.147272 · Cited by 112
Viethen, T., Gerhardt, F., Dumitrescu, D., Knoop-Busch, S., ten Freyhaus, H., Rudolph, T. K., Baldus, S. E., & Rosenkranz, S. (2014) · International Journal of Cardiology · doi:10.1016/j.ijcard.2014.04.233 · Cited by 116
Metadata
- Authors
- Anker, S. D., Comin Colet, J., Filippatos, G., Willenheimer, R., Dickstein, K., Drexler, H., Lüscher, T. F., Bart, B., Banasiak, W., Niegowska, J., Kirwan, B.-A., Mori, C., von Eisenhart Rothe, B., Pocock, S. J., Poole-Wilson, P. A., & Ponikowski, P.
- Affiliations
- Stavanger University Hospital (NO)
- Lund University (SE)
- University of Bergen (NO)
- Medizinische Hochschule Hannover (DE)
- University Hospital Zurich (CH)
- Pirogov Russian National Research Medical University (RU)
- State Oil Company of Azerbaijan Republic (Azerbaijan) (AZ)
- Vifor Pharma (Switzerland) (CH)
- London School of Hygiene & Tropical Medicine (GB)
- Imperial College London (GB)
- Wroclaw Medical University (PL)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2009-12-17
- Volume
- 361
- Issue
- 25
- Pages
- 2436-2448
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2148669301
- Cited by
- 2,083
- References
- 26
- Citations by year
- 2026: 101 · 2025: 131 · 2024: 145 · 2023: 156 · 2022: 162 · 2021: 190 · 2020: 128 · 2019: 129 · 2018: 113 · 2017: 133 · 2016: 101 · 2015: 115 · 2014: 102 · 2013: 93 · 2012: 106
- FWCI
- 62.22
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Zurich Open Repository and Archive (University of Zurich) (acceptedVersion, other-oa)
- LSHTM Research Online (London School of Hygiene and Tropical Medicine) (acceptedVersion)
- ABACUS. Repositorio de Producción Científica (Universidad Europea) (submittedVersion, other-oa)
- Dipòsit Digital de la Universitat de Barcelona (Universitat de Barcelona) (submittedVersion, public-domain)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, other-oa)
- Lund University Publications (Lund University) (submittedVersion, other-oa)
- University of Bedfordshire Repository (University of Bedfordshire) (submittedVersion)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion, other-oa)
- Zurich Open Repository and Archive (University of Zurich)
- Funders
- Amgen
- Teva Pharmaceutical Industries
- Vifor Pharma
- Servier
- Topics
- Health Sciences › Medicine › Hematology › Iron Metabolism and Disorders
- Health Sciences › Medicine › Hematology › Erythropoietin and Anemia Treatment
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Keywords
- ferric carboxymaltose, intravenous iron, chronic heart failure, iron deficiency, anemia, reduced left ventricular ejection fraction, NYHA functional class, symptom improvement, functional capacity, 6-minute walk test, health-related quality of life, ferritin, transferrin saturation, adverse events, mortality, serious adverse events, iron deficiency anemia
- MeSH terms
- Iron Deficiencies, Aged, Chronic Disease, Female, Ferric Compounds, Ferritins, Follow-Up Studies, Heart Failure, Hematinics, Humans, Male, Maltose, Quality of Life, Stroke Volume, Ventricular Dysfunction, Left, Anemia, Iron-Deficiency
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.